Cargando…
Human pharmacokinetics of XBD173 and etifoxine distinguish their potential for pharmacodynamic effects mediated by translocator protein
XBD173 and etifoxine are translocator protein (TSPO) ligands that modulate inflammatory responses in preclinical models. Limited human pharmacokinetic data is available for either molecule, and the binding affinity of etifoxine for human TSPO is unknown. To allow for design of human challenge experi...
Autores principales: | Owen, David R., Phillips, Alexandra, O’Connor, Desmond, Grey, Gabrielle, Aimola, Lina, Nicholas, Richard, Matthews, Paul M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545781/ https://www.ncbi.nlm.nih.gov/pubmed/35524344 http://dx.doi.org/10.1111/bcp.15392 |
Ejemplares similares
-
Chronic administration of XBD173 ameliorates cognitive deficits and neuropathology via 18 kDa translocator protein (TSPO) in a mouse model of Alzheimer’s disease
por: Pradhan, Arpit Kumar, et al.
Publicado: (2023) -
Translocator Protein Ligand Etifoxine Attenuates MPTP-Induced Neurotoxicity
por: Tian, Qi, et al.
Publicado: (2022) -
The agonistic TSPO ligand XBD173 attenuates the glial response thereby protecting inner retinal neurons in a murine model of retinal ischemia
por: Mages, Kristin, et al.
Publicado: (2019) -
Etifoxine for Pain Patients with Anxiety
por: Choi, Yun Mi, et al.
Publicado: (2015) -
Reduction of Traumatic Brain Damage by Tspo Ligand Etifoxine
por: Shehadeh, Mona, et al.
Publicado: (2019)